­­­Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease MZE001 was Well-tolerated and Reduced Glycogen Accumulation in Blood Cells and Muscle in Healthy Volunteers  Maze to Receive…